Global Neurologic Disorders Therapeutics Market Overview:
Global Neurologic Disorders Therapeutics Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2026-2035, Considering the Base Year As 2025.
Global Neurologic Disorders Therapeutics Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Neurologic Disorders Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Neurologic Disorders Therapeutics Market:
The Neurologic Disorders Therapeutics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Neurologic Disorders Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Neurologic Disorders Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Neurologic Disorders Therapeutics market has been segmented into:
Anticholinergic Drug Class
Analgesics Drug Class
Antiepileptic Drug Class
Other Drug Classes
By Application, Neurologic Disorders Therapeutics market has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies).
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Neurologic Disorders Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Neurologic Disorders Therapeutics market.
Top Key Players Covered in Neurologic Disorders Therapeutics market are:
AstraZeneca PLC
Biogen Inc.
Biohaven Ltd.
Eisai Co. Ltd.
H. Lundbeck A/S
Ionis Pharmaceuticals Inc.
Mitsubishi Tanabe Pharma Corporation
Neurelis Inc.
Neurocrine Biosciences Inc.
Neurona Therapeutics Inc.
Ovid Therapeutics Inc.
Pfizer Inc.
Sanofi SA
UCB SA
Voyager Therapeutics Inc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Neurologic Disorders Therapeutics Market Type
4.1 Neurologic Disorders Therapeutics Market Snapshot and Growth Engine
4.2 Neurologic Disorders Therapeutics Market Overview
4.3 Anticholinergic Drug Class
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Anticholinergic Drug Class: Geographic Segmentation Analysis
4.4 Analgesics Drug Class
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Analgesics Drug Class: Geographic Segmentation Analysis
4.5 Antiepileptic Drug Class
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Antiepileptic Drug Class: Geographic Segmentation Analysis
4.6 Other Drug Classes
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Other Drug Classes: Geographic Segmentation Analysis
Chapter 5: Neurologic Disorders Therapeutics Market Application
5.1 Neurologic Disorders Therapeutics Market Snapshot and Growth Engine
5.2 Neurologic Disorders Therapeutics Market Overview
5.3 Hospital Pharmacies
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Hospital Pharmacies: Geographic Segmentation Analysis
5.4 Retail Pharmacies
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Retail Pharmacies: Geographic Segmentation Analysis
5.5 Online Pharmacies).
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Online Pharmacies).: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Neurologic Disorders Therapeutics Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ASTRAZENECA PLC; BIOGEN
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; BIOHAVEN
6.4 LTD.; EISAI CO.
6.5 LTD.; H. LUNDBECK A/S; IONIS PHARMACEUTICALS
6.6 INC.; MITSUBISHI TANABE PHARMA CORPORATION; NEURELIS
6.7 INC.; NEUROCRINE BIOSCIENCES
6.8 INC.; NEURONA THERAPEUTICS
6.9 INC.; OVID THERAPEUTICS
6.10 INC.; PFIZER
6.11 INC.; SANOFI SA; UCB SA; VOYAGER THERAPEUTICS
6.12 INC.
Chapter 7: Global Neurologic Disorders Therapeutics Market By Region
7.1 Overview
7.2. North America Neurologic Disorders Therapeutics Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Anticholinergic Drug Class
7.2.2.2 Analgesics Drug Class
7.2.2.3 Antiepileptic Drug Class
7.2.2.4 Other Drug Classes
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Hospital Pharmacies
7.2.3.2 Retail Pharmacies
7.2.3.3 Online Pharmacies).
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Neurologic Disorders Therapeutics Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Anticholinergic Drug Class
7.3.2.2 Analgesics Drug Class
7.3.2.3 Antiepileptic Drug Class
7.3.2.4 Other Drug Classes
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Hospital Pharmacies
7.3.3.2 Retail Pharmacies
7.3.3.3 Online Pharmacies).
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Neurologic Disorders Therapeutics Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Anticholinergic Drug Class
7.4.2.2 Analgesics Drug Class
7.4.2.3 Antiepileptic Drug Class
7.4.2.4 Other Drug Classes
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Hospital Pharmacies
7.4.3.2 Retail Pharmacies
7.4.3.3 Online Pharmacies).
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Neurologic Disorders Therapeutics Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Anticholinergic Drug Class
7.5.2.2 Analgesics Drug Class
7.5.2.3 Antiepileptic Drug Class
7.5.2.4 Other Drug Classes
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Hospital Pharmacies
7.5.3.2 Retail Pharmacies
7.5.3.3 Online Pharmacies).
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Neurologic Disorders Therapeutics Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Anticholinergic Drug Class
7.6.2.2 Analgesics Drug Class
7.6.2.3 Antiepileptic Drug Class
7.6.2.4 Other Drug Classes
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Hospital Pharmacies
7.6.3.2 Retail Pharmacies
7.6.3.3 Online Pharmacies).
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Neurologic Disorders Therapeutics Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Anticholinergic Drug Class
7.7.2.2 Analgesics Drug Class
7.7.2.3 Antiepileptic Drug Class
7.7.2.4 Other Drug Classes
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Hospital Pharmacies
7.7.3.2 Retail Pharmacies
7.7.3.3 Online Pharmacies).
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Neurologic Disorders Therapeutics Scope:
|
Report Data
|
Neurologic Disorders Therapeutics Market
|
|
Neurologic Disorders Therapeutics Market Size in 2025
|
USD XX million
|
|
Neurologic Disorders Therapeutics CAGR 2025 - 2032
|
XX%
|
|
Neurologic Disorders Therapeutics Base Year
|
2024
|
|
Neurologic Disorders Therapeutics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
AstraZeneca PLC, Biogen Inc., Biohaven Ltd., Eisai Co. Ltd., H. Lundbeck A/S, Ionis Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Neurelis Inc., Neurocrine Biosciences Inc., Neurona Therapeutics Inc., Ovid Therapeutics Inc., Pfizer Inc., Sanofi SA, UCB SA, Voyager Therapeutics Inc..
|
|
Key Segments
|
By Type
Anticholinergic Drug Class
Analgesics Drug Class
Antiepileptic Drug Class
Other Drug Classes
By Applications
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies).
|
